Your browser doesn't support javascript.
loading
Reconstitution of the alternative pathway of the complement system enables rapid delineation of the mechanism of action of novel inhibitors.
Goodrich, Andrew C; LeClair, Norbert P; Shillova, Nita; Morton, William D; Wittwer, Arthur J; Loyet, Kelly M; Hannoush, Rami N.
Afiliação
  • Goodrich AC; Department of Early Discovery Biochemistry, Genentech, South San Francisco, California, USA. Electronic address: agoodri6@gmail.com.
  • LeClair NP; Department of Biochemical and Cellular Pharmacology, Genentech, South San Francisco, California, USA.
  • Shillova N; Department of Biochemistry, Confluence Discovery Technologies Inc, St Louis, Missouri, USA.
  • Morton WD; Department of Biochemistry, Confluence Discovery Technologies Inc, St Louis, Missouri, USA.
  • Wittwer AJ; Department of Biochemistry, Confluence Discovery Technologies Inc, St Louis, Missouri, USA.
  • Loyet KM; Department of Biochemical and Cellular Pharmacology, Genentech, South San Francisco, California, USA.
  • Hannoush RN; Department of Early Discovery Biochemistry, Genentech, South San Francisco, California, USA. Electronic address: ramihannoush@gmail.com.
J Biol Chem ; 300(7): 107467, 2024 Jul.
Article em En | MEDLINE | ID: mdl-38876307
ABSTRACT
The complement system plays a critical role in the innate immune response, acting as a first line of defense against invading pathogens. However, dysregulation of the complement system is implicated in the pathogenesis of numerous diseases, ranging from Alzheimer's to age-related macular degeneration and rare blood disorders. As such, complement inhibitors have enormous potential to alleviate disease burden. While a few complement inhibitors are in clinical use, there is still a significant unmet medical need for the discovery and development of novel inhibitors to treat patients suffering from disorders of the complement system. A key hurdle in the development of complement inhibitors has been the determination of their mechanism of action. Progression along the complement cascade involves the formation of numerous multimeric protein complexes, creating the potential for inhibitors to act at multiple nodes in the pathway. This is especially true for molecules that target the central component C3 and its fragment C3b, which serve a dual role as a substrate for the C3 convertases and as a scaffolding protein in both the C3 and C5 convertases. Here, we report a step-by-step in vitro reconstitution of the complement alternative pathway using bio-layer interferometry. By physically uncoupling each step in the pathway, we were able to determine the kinetic signature of inhibitors that act at single steps in the pathway and delineate the full mechanism of action of known and novel C3 inhibitors. The method could have utility in drug discovery and further elucidating the biochemistry of the complement system.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Via Alternativa do Complemento Limite: Humans Idioma: En Revista: J Biol Chem Ano de publicação: 2024 Tipo de documento: Article País de publicação: Estados Unidos

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Via Alternativa do Complemento Limite: Humans Idioma: En Revista: J Biol Chem Ano de publicação: 2024 Tipo de documento: Article País de publicação: Estados Unidos